ML22073A267
| ML22073A267 | |
| Person / Time | |
|---|---|
| Site: | 03020372 |
| Issue date: | 04/05/2022 |
| From: | Latischa Hanson NRC Region 4 |
| To: | Alliance HealthCare Services, Diagnostic Health Center of Anchorage |
| References | |
| Download: ML22073A267 (3) | |
See also: IR 05000232/2014001
Text
U.S. NUCLEAR REGULATORY COMMISSION
MATERIALS LICENSE
PAGE
OF
1
3
Amendment No. 24
PAGES
Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I,
Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued
authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s)
and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This
license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and
orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.
Licensee
Anchorage, AK 99508
2. 4100 Lake Otis Parkway #102
A wholly owned subsidiary of Alliance HealthCare
Services
1. Diagnostic Health Center of Anchorage, LLC
4. Expiration Date: March 31, 2025
Docket No.:
5.
030-20372
License No.: 50-23214-01 is
amended in its entirety to read as
follows:
Reference No.:
3.
In accordance with letter dated
July 6, 2021
6.
7.
8.
Byproduct, source,
and/or special nuclear
material
Chemical and/or physical form
Maximum amount that licensee
may possess at any one time
under this license
9.
Authorized use
A.
A.
A.
A.
For use in uptake, dilution and
excretion studies permitted by 10 CFR
35.100.
Any
As Needed
Any byproduct material
permitted by 10 CFR 35.100
B.
B.
B.
B.
For use in imaging and localization
studies permitted by 10 CFR 35.200.
Any
As Needed
Any byproduct material
permitted by 10 CFR 35.200
C.
C.
C.
C.
Any sodium iodide Iodine-131 use
permitted by 10 CFR 35.300 for which
the patient can be released under the
provisions of 10 CFR 35.75.
Any
500 millicuries total
D.
D.
D.
D.
For use in in-vitro studies.
Prepackaged Kits
50 millicuries total
Any byproduct material
permitted by 10 CFR 31.11
License No.:
Docket or Reference No.:
U.S. NUCLEAR REGULATORY COMMISSION
MATERIALS LICENSE
SUPPLEMENTARY SHEET
PAGES
OF
PAGE
3
2
50-23214-01
030-20372
Amendment No. 24
CONDITIONS
10. Licensed material may be used only at the licensees facilities located at Lake Otis Medical Plaza, 4100 Lake Otis Parkway #102,
Anchorage, Alaska.
11.
The Radiation Safety Officer for this license is Kay Kassel, MS, CNMT.
12. Licensed material shall only be used by, or under the supervision of:
A.
Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
B.
The following individuals are authorized users for the material and medical uses as indicated:
Authorized Users
Material and Use
Marc R. Beck, M.D.
35.100; 35.200; Oral administration of sodium iodide I-131; 31.11
Robert L. Bridges, M.D.
35.100; 35.200; Oral administration of sodium iodide I-131; 31.11
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the
minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
License No.:
Docket or Reference No.:
U.S. NUCLEAR REGULATORY COMMISSION
MATERIALS LICENSE
SUPPLEMENTARY SHEET
PAGES
OF
PAGE
3
3
50-23214-01
030-20372
Amendment No. 24
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements,
representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to
those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the
licensees ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory
Commissions regulations shall govern unless the statements, representations, and procedures in the licensees application and
correspondence are more restrictive than the regulations.
A. Application dated October 20, 2014 (ML14336A723)
B. Letter dated February 16, 2015 with enclosures (ML15061A178)
C. Letter dated July 6, 2021 (ML21196A052)
FOR THE U.S. NUCLEAR REGULATORY COMMISSION
By:
Date:
Latischa M. Hanson
Region IV
April 5, 2022
Latischa M. Hanson
Digitally signed by Latischa M.
Hanson
Date: 2022.04.05 19:20:39 -05'00'